Related Experiment Video
Updated: Jan 22, 2026

Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging
Published on: June 15, 2020
Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance
Maria Jove1, Jade Spencer2, Malcolm Clench3
1Medical Oncology department, Institut Català d'Oncologia, Barcelona, Spain; Leeds Institute of Cancer Studies and Pathology, University of Leeds, Leeds, UK.
Abstract:
Failure of systemic cancer treatment can be, at least in part, due to the drug not being delivered to the tumour at sufficiently high concentration and/or sufficiently homogeneous distribution; this is termed as "pharmacokinetic drug resistance". To understand whether a drug is being adequately delivered to the tumour, "precision pharmacology" techniques are needed. Mass spectrometry imaging (MSI) is a relatively new and complex technique that allows imaging of drug distribution within tissues. In this review we address the applicability of MSI to the study of cancer drug distribution from the bench to the bedside. We address: (i) the role of MSI in pre-clinical studies to characterize anti-cancer drug distribution within the body and the tumour, (ii) the application of MSI in pre-clinical studies to define optimal drug dose or schedule, combinations or new drug delivery systems, and finally (iii) the emerging role of MSI in clinical research.
Insights
Precision pharmacology using mass spectrometry imaging (MSI) can overcome pharmacokinetic drug resistance in cancer treatment. MSI precisely maps drug distribution in tumors, guiding optimized dosing and delivery for better therapeutic outcomes.
Area of Science:
- Pharmacology
- Analytical Chemistry
- Oncology
Background:
- Systemic cancer treatment failure is often linked to inadequate drug delivery to tumors, a phenomenon known as pharmacokinetic drug resistance.
- Understanding drug distribution is crucial for effective cancer therapy.
- Precision pharmacology offers advanced techniques to address these delivery challenges.
Purpose of the Study:
- To review the application of mass spectrometry imaging (MSI) in studying cancer drug distribution.
- To explore MSI's utility from preclinical research to clinical applications.
- To highlight MSI's role in overcoming pharmacokinetic drug resistance.
Main Methods:
- Mass spectrometry imaging (MSI) for visualizing drug distribution in tissues.
- Review of preclinical studies characterizing anti-cancer drug distribution.
- Analysis of MSI applications in optimizing drug dose, schedule, combinations, and delivery systems.
- Examination of MSI's emerging role in clinical cancer research.
Main Results:
- MSI enables detailed characterization of drug distribution within the body and tumor microenvironment.
- MSI aids in defining optimal dosing strategies, drug combinations, and novel drug delivery systems.
- MSI is increasingly valuable in translational cancer research, bridging preclinical findings to clinical settings.
Conclusions:
- Mass spectrometry imaging is a powerful tool for precision pharmacology in oncology.
- MSI facilitates a deeper understanding of drug pharmacokinetics and distribution in cancer.
- The application of MSI is expanding from benchtop research to clinical practice, promising improved cancer treatment efficacy.
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Tandem Mass Spectrometry
Mass Spectrometry: Overview
Mass Spectrometry of Amines
Mass Spectrometry: Isotope Effect

